While interfering with insulin signaling may be clinically problematic because of its potential deleterious effects on glycemia, chronotherapeutic targeting of peripheral incretin signaling may provide an alternative therapeutic strategy against metabolic disorders arising from circadian strain as observed in shift workers or during jetlag. The gene discussed is GCG; the disease is metabolic disease.